Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 65,630 shares, an increase of 32.0% from the December 15th total of 49,723 shares. Approximately 1.3% of the shares of the company are short sold. Based on an average trading volume of 78,479 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 78,479 shares, the short-interest ratio is currently 0.8 days. Approximately 1.3% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $3.50.

Evogene Stock Performance

Shares of NASDAQ:EVGN opened at $1.05 on Tuesday. The firm has a market capitalization of $5.64 million, a PE ratio of -2.10 and a beta of 1.28. Evogene has a 1-year low of $0.93 and a 1-year high of $2.42. The business’s 50 day moving average is $1.09 and its 200-day moving average is $1.20.

Evogene (NASDAQ:EVGN) last issued its earnings results on Thursday, November 20th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10. Evogene had a negative return on equity of 75.09% and a negative net margin of 52.33%.The business had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.65 million.

Institutional Trading of Evogene

An institutional investor recently raised its position in Evogene stock. Citadel Advisors LLC boosted its holdings in Evogene Ltd. (NASDAQ:EVGN) by 169.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,575 shares of the biotechnology company’s stock after acquiring an additional 36,206 shares during the quarter. Citadel Advisors LLC owned 1.07% of Evogene worth $66,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.